These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 38189180)

  • 1. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
    Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
    Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
    Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
    Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
    Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Black PC; Tangen CM; Singh P; McConkey DJ; Lucia MS; Lowrance WT; Koshkin VS; Stratton KL; Bivalacqua TJ; Kassouf W; Porten SP; Bangs R; Plets M; Thompson IM; Lerner SP
    Eur Urol; 2023 Dec; 84(6):536-544. PubMed ID: 37596191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
    Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
    Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
    PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes.
    Li H; Wang L; Li H; Zhang P; Li Z; Xue L; Wang Z; Fu D; Chen Q; Luo Q; Chong T; Wang Z
    Oncology; 2024; 102(4):337-342. PubMed ID: 37647883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multi-Gene Signature of Non-Muscle-Invasive Bladder Cancer Identifies Patients Who Respond to Immunotherapies Including Bacillus Calmette-Guérin and Immune Checkpoint Inhibitors.
    Baek SW; Leem SH
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
    Tan X; Liu Z; Cai T; Wang Y; Wu Z; Qin Z; Li Z; Liu Z; Yuan G; Zhou Q; Yao K
    Eur Urol Oncol; 2024 Aug; 7(4):760-769. PubMed ID: 37884420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
    Durant AM; Choudry MM; Madura G; Mi L; Faraj KS; Tyson MD
    Urol Oncol; 2024 Jan; 42(1):21.e21-21.e28. PubMed ID: 37852817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study.
    Hahn NM; O'Donnell MA; Efstathiou JA; Zahurak M; Rosner GL; Smith J; Kates MR; Bivalacqua TJ; Tran PT; Song DY; Baras AS; Matoso A; Choi W; Smith KN; Pardoll DM; Marchionni L; McGuire B; Grace Phelan M; Johnson BA; O'Neal T; McConkey DJ; Rose TL; Bjurlin M; Lim EA; Drake CG; McKiernan JM; Deutsch I; Anderson CB; Lamm DL; Geynisman DM; Plimack ER; Hallman MA; Horwitz EM; Al-Saleem E; Chen DYT; Greenberg RE; Kutikov A; Guo G; Masterson TA; Adra N; Kaimakliotis HZ
    Eur Urol; 2023 Jun; 83(6):486-494. PubMed ID: 36717286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
    Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
    Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
    Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
    Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with Non-Muscle-Invasive Bladder Cancer Previously Treated with Nephroureterectomy Have a High Risk of Recurrence after Bacillus Calmette-Guérin Intravesical Instillation Therapy.
    Maeyama R; Ikeda M; Shimura S; Amano N; Murakami Y; Yamada Y; Koguchi D; Tachibana T; Kawamura M; Sakata Y; Hagiwara M; Matsumoto K; Iwamura M
    Chemotherapy; 2023; 68(4):190-196. PubMed ID: 35390791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.